The estimated Net Worth of John Franklin Fowler is at least $3.76 Milion dollars as of 10 November 2022. Mr. Fowler owns over 27,000 units of Kezar Life Sciences Inc stock worth over $228,464 and over the last 6 years he sold KZR stock worth over $0. In addition, he makes $3,532,020 as Chief Executive Officer a Director at Kezar Life Sciences Inc.
John has made over 8 trades of the Kezar Life Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 27,000 units of KZR stock worth $24,300 on 10 November 2022.
The largest trade he's ever made was exercising 50,000 units of Kezar Life Sciences Inc stock on 19 December 2019 worth over $45,000. On average, John trades about 9,561 units every 79 days since 2018. As of 10 November 2022 he still owns at least 393,904 units of Kezar Life Sciences Inc stock.
You can see the complete history of Mr. Fowler stock trades at the bottom of the page.
John Franklin Fowler is Chief Executive Officer, Director of the Company. Prior to founding our company, Mr. Fowler was Chief Executive Officer of HealthCPA, a provider of patient advocacy and insurance navigation services, from June 2009 to October 2014. Mr. Fowler received his A.B. and M.B.A. degrees from Stanford University.
As the Chief Executive Officer a Director of Kezar Life Sciences Inc, the total compensation of John Fowler at Kezar Life Sciences Inc is $3,532,020. There are no executives at Kezar Life Sciences Inc getting paid more.
John Fowler is 48, he's been the Chief Executive Officer a Director of Kezar Life Sciences Inc since 2015. There are 10 older and 3 younger executives at Kezar Life Sciences Inc. The oldest executive at Kezar Life Sciences Inc is Franklin Berger, 70, who is the Independent Director.
John's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... a Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: